SCHEMBL20732298

SCHEMBL20732298

CN(C(=O)OC(C)(C)C)C(C(=O)O)C(C)(C)c1ccc(OC(=O)OC(C)(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.48
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 1/20 0.39
MMP13 P45452 1/20 0.38
KDM1A O60341 1/20 0.38
MAPT P10636 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CA2 P00918 1/20 0.33
BCHE P06276 2/20 0.32
CHRM2 P08172 1/20 0.32
KDM4E B2RXH2 2/20 0.32
POLB P06746 1/20 0.32
ALDH1A1 P00352 2/20 0.32
NPY5R Q15761 1/20 0.32
PKM P14618 1/20 0.31
SRD5A1 P18405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805547 0.87 MAPT (0.38) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL20732299 0.84 ESR1 (0.36) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL22069882 0.84 ESR1 (0.36) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL88460 0.84 MMP13 (0.40) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL58396 0.84 MMP13 (0.40) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL5981030 0.84 MMP13 (0.40) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL20723962 0.83 AAK1 (0.35) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL16176598 0.83 AAK1 (0.40) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL16176596 0.83 AAK1 (0.40) RAB9AKMT2ANPSR1MEN1MMP13
SCHEMBL6675259 0.82 CA12 (0.39) KMT2ANPSR1MMP13MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312419-B2 Hemiasterlin derivative having cysteine residue Sumitomo Pharma Co., Ltd. (JP) 2025-05-27 US disclosed
EP-3666787-B9 ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE SUMITOMO PHARMA CO LTD (JP) 2024-08-28 EP disclosed
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same Sumitomo Pharma Co., Ltd. (JP) 2024-06-25 US disclosed
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same Sumitomo Pharma Co., Ltd. (JP) 2024-06-25 US disclosed
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same Sumitomo Pharma Co., Ltd. (JP) 2024-06-25 US disclosed
EP-3666787-B1 ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE SUMITOMO PHARMA CO LTD (JP) 2024-02-21 EP disclosed
EP-4321523-A2 HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME Sumitomo Pharma Co., Ltd. (JP) 2024-02-14 EP disclosed
US-11795195-B2 Antibody-drug conjugates including hemiasterlin derivative Sumitomo Pharma Co., Ltd. (JP) 2023-10-24 US disclosed
US-11795195-B2 Antibody-drug conjugates including hemiasterlin derivative Sumitomo Pharma Co., Ltd. (JP) 2023-10-24 US disclosed
US-11795195-B2 Antibody-drug conjugates including hemiasterlin derivative Sumitomo Pharma Co., Ltd. (JP) 2023-10-24 US disclosed
US-20200247847-A1 Antibody-Drug Conjugates Including Hemiasterlin Derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-08-06 US disclosed
US-20200247847-A1 Antibody-Drug Conjugates Including Hemiasterlin Derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-08-06 US disclosed
EP-3666788-A1 HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME Sumitomo Dainippon Pharma Co., Ltd. (JP) 2020-06-17 EP disclosed
EP-3666788-A1 HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME Sumitomo Dainippon Pharma Co., Ltd. (JP) 2020-06-17 EP disclosed
EP-3666787-A1 ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2020-06-17 EP disclosed
EP-3666787-A1 ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2020-06-17 EP disclosed
CN-111051329-A Hamiltrin derivatives and antibody drug complexes thereof 大日本住友制药株式会社 2020-04-21 CN disclosed
CN-111032676-A Antibody drug complex comprising a hemiasterlin derivative 大日本住友制药株式会社 2020-04-17 CN disclosed
WO-2019031614-A1 ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE 大日本住友製薬株式会社 2019-02-14 WO disclosed
WO-2019031615-A1 HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME 大日本住友製薬株式会社 2019-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312419-B2 Hemiasterlin derivative having cysteine residue SHBG, CYP11A1, CYP11B1 ELANE 2944/4885RAB9A 1315/4885KMT2A 3110/4885
US-11795195-B2 Antibody-drug conjugates including hemiasterlin derivative HSD3B2, HSD3B1, HSD11B2 ELANE 3697/4885RAB9A 1141/4885KMT2A 2112/4885
US-20200247847-A1 Antibody-Drug Conjugates Including Hemiasterlin Derivative HSD3B2, HSD3B1, HSD11B2 ELANE 3697/4885RAB9A 1141/4885KMT2A 2112/4885
US-12018093-B2 Hemiasterlin derivatives and antibody-drug conjugates including same FCGRT, QARS1, INHA ELANE 4511/4885RAB9A 740/4885KMT2A 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.